Ert Pompe denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS May Deny ERT for Pompe Disease on Medical-Necessity Grounds

Blue Cross Blue Shield medical-necessity denials for enzyme replacement therapy (ERT) in Pompe disease typically occur when the prior authorization submission lacked the clinical detail the plan requires to confirm: (1) the Pompe disease diagnosis is definitively established, (2) the patient's functional and clinical status meets the coverage criteria, and (3) the prescribing clinician has the specialty background the plan expects. These denials are not a finding that ERT does not work — they are a finding that the plan did not receive adequate documentation to make that determination. That gap is correctable.

## Why This Denial Is Appealable

Medical-necessity denials carry the most robust appeal protections of any denial type. If the clinical evidence in the chart supports the diagnosis and the need for ERT, a well-constructed appeal — organized to map each plan criterion to a specific documented fact — succeeds at internal review in a meaningful portion of cases. Even when it does not, external review is available and independent reviewers apply generally accepted clinical standards, not the insurer's internal benchmark.

## Federal Appeal Framework

• Internal appeal: File within the deadline on the denial letter (typically 180 days). Given the progressive and serious nature of Pompe disease, request expedited review. BCBS must respond to expedited appeals within 72 hours and standard appeals within 30 days.
• External review (ACA §2719): Available after final internal denial. The IRO assesses whether the denial is consistent with evidence-based clinical standards. The external-review window is generally four months from final internal denial.
• ERISA §503 (employer-sponsored plans): Request the complete claims file, including the specific coverage criteria applied, the reviewer's credentials, and any clinical guidelines the plan relied on.
• Expedited external review: Available when the standard timeline would seriously jeopardize life, health, or ability to regain maximum function — applicable to untreated or under-treated Pompe disease.

## Documentation to Gather

• Confirmed diagnosis: Genetic testing (GAA mutation analysis) and/or enzyme activity assay, with the interpreting clinician identified — this is the foundation of the appeal.
• Baseline and current functional assessments: Timed function tests, respiratory function evaluations, motor assessments, and any other objective measures of disease status and progression documented in the chart.
• Disease progression narrative: Clinical notes showing how the patient's condition has evolved over time, establishing the urgency and trajectory.
• Specialist prescriber documentation: Credentials of the ordering physician confirming specialty alignment with the plan's requirements.
• Medical necessity letter: A detailed, criterion-by-criterion letter from the treating specialist that addresses each element of BCBS's coverage policy directly and cites the FDA-approved prescribing label and applicable specialist-society guidelines by organization name.

## Criteria-Mapping Structure

Obtain the current BCBS medical policy for ERT in Pompe disease and list every coverage criterion. For each one, provide the specific chart fact that satisfies it:

| BCBS Coverage Criterion | Satisfying Documentation | |---|---| | Confirmed Pompe disease diagnosis | [Genetic/enzyme test report, date, interpreting clinician] | | Clinical severity or functional status requirement | [Objective test results from chart] | | Specialist prescriber requirement | [Physician specialty documentation] | | FDA-approved label indication | [Label excerpt for the specific product] | | Prior treatment history (if required) | [Treatment timeline with dates and outcomes] |

A criterion-mapped appeal letter is dramatically more effective than a general submission. Address every element the plan listed, with page-referenced exhibit attachments.